Search results
Found 6074 matches for
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Amber Thompson
Researchers and Research Support M-Z
Amber Thompson - Senior QA and Sample Compliance Manager
Gulnar Abdullayeva
Researchers and Research Support A-L
Gulnar Abdullayeva - Postdoctoral Research Scientist in Outbreak Pathogens
Mary Deadman
Researchers and Research Support A-L
B. Sc. (Hons), M. Sc. (Oxon) Mary Deadman - Laboratory Manager
Hasan Nisar
Departmental Administration
Hasan Nisar - Clinical Trials Receptionist and Administrator
Michelle Fernandes
MBBS, MRCPCH, DPhil (Oxon) Michelle Fernandes - Clinical Lecturer & MRC Clinical Research Training Fellow
Lee Page
Researchers and Research Support M-Z
BSc (Hons), MSc, PhD Lee Page - Postdoctoral Research Scientist